Compounds > oxybutynin

oxybutynin and sertraline

oxybutynin has been researched along with sertraline in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	4 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cianchetta, G; Cruciani, G; Fravolini, A; Giesing, D; Singleton, RW; Vaz, RJ; Wildgoose, M; Zhang, M	1
Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

1 review(s) available for oxybutynin and sertraline

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

5 other study(ies) available for oxybutynin and sertraline

Article	Year
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Fluoresceins; Fluorescent Dyes; Humans; Models, Molecular; Multivariate Analysis; Permeability; Quantitative Structure-Activity Relationship	2005
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model. Journal of medicinal chemistry, 2008, Jan-24, Volume: 51, Issue:2 Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase	2008
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10 Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012